BACKGROUND: Approximately 30% of thyroid cancer patients present with reappearing disease within 40 years of initial diagnosis. Hence, sensitive postsurgical monitoring techniques are imperative to successful long-term care. The objective of this study was to assess the added clinical utility of a combined positron emission tomography/magnetic resonance imaging (PET/MRI) of the neck in conjunction with standard imaging in the detection of recurrent thyroid carcinoma. We define standard imaging as a neck sonogram, 131I scan, computed tomography, and MRI. METHODS: This study included 34 patients treated for thyroid cancer at Washington Hospital Center. All patients had previously undergone near-total or total thyroidectomy, standard follow-up imaging studies, and laboratory studies. Twenty-nine of thirty-four patients had received at least one 131I treatment prior to the study. Each patient received a PET and MRI scan, and these images were subsequently digitally fused. RESULTS: Individually and blinded, four endocrinologists retrospectively reviewed all information in patient charts prior to PET and PET/MRI coregistration. A clinical assessment and treatment plan were devised with these data. Following the initial assessment, the endocrinologists were provided results from the PET and PET/MRI fusion studies and asked to make a revised assessment and treatment plan. For each patient, the physicians categorized PET/MRI fusion results as providing new information that altered the initial treatment plan, providing new information that confirmed the initial treatment plan, or providing no additional information. On average, PET/MRI coregistration provided additional information that altered the treatment plan in 46% of the cases, provided additional information that confirmed the treatment plan in 36% of cases, and did not provide any additional information in 18% of cases. CONCLUSION: The combination of structural and functional data that PET/neck MRI fusion offers provided further information in an overwhelming majority of thyroid cancer patients in this study. Thus PET/MRI can be a useful tool in surgical planning, radioactive iodine therapy decisions, and determining the level of follow-up necessary for each patient.
BACKGROUND: Approximately 30% of thyroid cancerpatients present with reappearing disease within 40 years of initial diagnosis. Hence, sensitive postsurgical monitoring techniques are imperative to successful long-term care. The objective of this study was to assess the added clinical utility of a combined positron emission tomography/magnetic resonance imaging (PET/MRI) of the neck in conjunction with standard imaging in the detection of recurrent thyroid carcinoma. We define standard imaging as a neck sonogram, 131I scan, computed tomography, and MRI. METHODS: This study included 34 patients treated for thyroid cancer at Washington Hospital Center. All patients had previously undergone near-total or total thyroidectomy, standard follow-up imaging studies, and laboratory studies. Twenty-nine of thirty-four patients had received at least one 131I treatment prior to the study. Each patient received a PET and MRI scan, and these images were subsequently digitally fused. RESULTS: Individually and blinded, four endocrinologists retrospectively reviewed all information in patient charts prior to PET and PET/MRI coregistration. A clinical assessment and treatment plan were devised with these data. Following the initial assessment, the endocrinologists were provided results from the PET and PET/MRI fusion studies and asked to make a revised assessment and treatment plan. For each patient, the physicians categorized PET/MRI fusion results as providing new information that altered the initial treatment plan, providing new information that confirmed the initial treatment plan, or providing no additional information. On average, PET/MRI coregistration provided additional information that altered the treatment plan in 46% of the cases, provided additional information that confirmed the treatment plan in 36% of cases, and did not provide any additional information in 18% of cases. CONCLUSION: The combination of structural and functional data that PET/neck MRI fusion offers provided further information in an overwhelming majority of thyroid cancerpatients in this study. Thus PET/MRI can be a useful tool in surgical planning, radioactive iodine therapy decisions, and determining the level of follow-up necessary for each patient.
Authors: James Nagarajah; Walter Jentzen; Verena Hartung; Sandra Rosenbaum-Krumme; Christian Mikat; Till Alexander Heusner; Gerald Antoch; Andreas Bockisch; Alexander Stahl Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-08 Impact factor: 9.236
Authors: Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger Journal: Eur J Nucl Med Mol Imaging Date: 2016-06 Impact factor: 9.236
Authors: I Binse; T D Poeppel; M Ruhlmann; B Gomez; L Umutlu; A Bockisch; S J Rosenbaum-Krumme Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-19 Impact factor: 9.236
Authors: Maryam Aghighi; Laura Jean Pisani; Ziyan Sun; Christopher Klenk; Himani Madnawat; Sandra Luna Fineman; Ranjana Advani; Rie Von Eyben; Daniel Owen; Andrew Quon; Michael Moseley; Heike E Daldrup-Link Journal: Eur Radiol Date: 2016-04-05 Impact factor: 5.315
Authors: Denys J Loeffelbein; Michael Souvatzoglou; Veronika Wankerl; Julia Dinges; Lucas M Ritschl; Thomas Mücke; Anja Pickhard; Matthias Eiber; Markus Schwaiger; Ambros J Beer Journal: BMC Cancer Date: 2014-11-19 Impact factor: 4.430